Skip to main content
Premium Trial:

Request an Annual Quote

Suzhou Ribo Life Sciences Takes License to Life Tech siRNA Drug-delivery Technology

Premium

Life Technologies announced this week that it has signed a licensing agreement giving Suzhou Ribo Life Sciences the exclusive rights to use its Invivofectamine Rx delivery technology in the development and manufacturing of siRNA therapeutics in China.

Life Technologies said that it stands to receive milestones and royalties on the sale of products incorporating the technology. Additional terms of the arrangement were not disclosed.

"Adding Life's Invivofectamine Rx formulation technology into our development efforts will significantly increase our ability to bring new siRNA therapeutics to Chinese patients with unmet medical needs," Ribo CEO Zicai Liang said in a statement. "We look forward to bringing our first Invivofectamine Rx-based program targeting hepatitis B into the clinic in a relatively short period of time."

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.